Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by one-, two- and three-compartment models using Bayesian and non-linear least squares methods

Pharmacological Research

Volumn 34, Issue 1-2, 1996, Pages 47-57

  Wu, Guang ^a   Cossettini, Paolo ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Bayesian method; Compartmental model; Cyclosporine; Haematological patient with multidrug resistance; Non linear least squares method; Prediction

Indexed keywords

CYCLOSPORIN A;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0030184843     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0063     Document Type: Article

References (56)

1. 1. Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 1985; 28: 51-75.
2. 2. Hall AG, Cattan AR. Drug resistance mechanisms in leukaemia. Bailliere's Clin Haematol 1991; 4: 655-75.
3. 3. Rothenberg M, Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 1989; 81: 907-13.
4. 4. Maria JP, Zittoun R, Sikic BI. Multidrug resistance (mdr 1) gene expression in acute leukemias: correlations with treatment outcome and in vivo drug sensitivity. Blood 1991; 78: 586-92.
5. 5. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24.
6. 6. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992; 31: 205-13.
7. 7. Nooter K, Oostrom R, Jonker R, van Dekken H, Stokdijk W, van den Engh G. Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother Pharmacol 1989; 23: 296-300.
8. 8. Slater L, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vivo. J Clin Invest 1986; 77: 1405-8.
9. 9. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
10. 10. Buffington DE, Lampasona V, Chandler MHH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205-16.
11. 11. Anderson JE, Munday AS, Kelman AW, Whiting B, Briggs JD, Knepil J, Thomson AH. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther Drug Monit 1994; 16: 160-5.
12. 12. Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, Van Thiel DH, Sanghvi A, Rosenthal JT. Cyclosporine kinetics in healthy volunteers. Clin Pharmacol 1987; 27: 243-8.
13. 13. Gardier AM, Methé D, Guédeney X, Barré J, Benvenutti C, Navarro N, Vernillet L, Loisance D, Cachera J-P, Jacotot B, Tillement J-P. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit 1993; 15: 274-80.
14. 14. Kovarik JM, Vernillet L, Mueller EA, Freiburghaus R, Niederberger W, Kutz K. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1994; 16: 519-25.
15. 15. Galla F, Marzocchi V, Croattino L, Poz D, Baraldo M, Furlanut M. Oral and intravenous disposition of cyclosporine in psoriatic patients. Ther Drug Monit 1995; 17: 302-4.
16. 16. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Loertscher B, Lemaire M, Nussbaumer K, Niederberger W, Wood A. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 1983; 34: 638-43.
17. 17. Karlsson MO, Lindberg-Freijs A. Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. J Pharmacokinet Biopharm 1990; 18: 293-311.
18. 18. Bernareggi B, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 21-50.
19. 19. Sheiner LB, Beal SL, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305.
20. 20. Sheiner LB, Beal SL. Bayesian individualisation of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344-8.
21. 21. Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetics. Clin Pharm 1984; 3: 525-30.
22. 22. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-67.
23. R Pharmacokinetic System Operations Manual. 6-45.
24. 24. Vozeh S, Steimer J-L. Feedback control mechanisms for drug dosage optimisation: concepts, classification and clinical application. Clin Pharmacokinet 1985; 10: 457-76.
25. 25. Mood AM, Graybill FA, Boes DC. Introduction to the theory of statistics. 3rd ed. London: McGraw-Hill Book Company, 1988: 36.
26. 26. PCNONLIN User Guide. version 4.2, Error Messages-11, 14.
27. 27. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drug 1993; 45: 953-1040.
28. 28. Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther Drug Monit 1989; 11: 269-75.
29. 29. Moyer TP, Winkels J, Krom R, Wiesner R. Evaluation of Abbot TDx monoclonal assay for monitoring cyclosporine in the whole blood [Tech Brief]. Clin Chem 1991; 37: 1120-1.
30. 30. Metzler CM, Elfring GL, McEwen AJ. A package of programs for pharmacokinetic modeling. Biometrics 1974; 30: 562-3.
31. 31. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-75.
32. 32. Cantarovich F, Bizollon C, Cantarovich D, Lefrançois N, Dubermard JM, Traeger J. Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy. Transplantation 1988; 45: 389-94.
33. 33. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905-8.
34. 34. Johnston A, Sketris I, Marsden JT, Galustian CG, Fashola T, Taube D, Pepper J, Holt DW. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990; 22: 1345-6.
35. 35. Meyer M, Bennet W, Udeajan J, Munar M. Evaluation of the efficacy of area under the curve (AUC) cyclosporine (CSA) monitoring. J Am Soc Nephrol 1991; 2: 808.
36. 36. Wu G, Baraldo M, Furlanut M. Calculating percentage prediction error: a user's note. Pharmacol Res 1995; 32: 241-8.
37. 37. Healy MJR. Outliers in clinical chemistry quality control schemes. Clin Chem 1979; 25: 675-7.
38. 38. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
39. 39. Wu G. Calculating predictive performance: a user's note. Pharmacol Res 1995; 31: 393-9.
40. 40. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. Br Med J 1988; 296: 1454-6.
41. 41. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107-32.
42. 42. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-95.
43. R Pharmacokinetic System Operations Manual. 6-51.
44. 44. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J. Individualising gentamicin dosage regimens: a comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991; 21: 461-78.
45. 45. Kelman AW, Whiting B, Bryson SM. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol 1982; 14: 247-56.
46. 46. Wu G, Baraldo M, Pea F, Cossettini P, Furlanut M. Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by Bayesian and non-linear least squares methods. Pharmacol Res 1995; 32: 355-62.
47. 47. Wu G, Pea F, Cossettini P, Furlanut M. Effects of number of samples for individualization on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by Bayesian and non-linear least squares methods. Pharmacol Res (revised).
48. R Pharmacokinetic System Operations Manual. 6-44-5.
49. 49. Pryka RD, Rodvold KA, Garrison M, Rotschsfer JC. Individualizing vancomycin dosage regimens: one-versus two-compartment Bayesian models. Ther Drug Monit 1989; 11: 450-4.
50. 50. Rodvold KA, Rotschafer JC, Gilliland SS, Guay DRP, Vance-Bryan K. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies. Ther Drug Monit 1994; 16: 37-41.
51. 51. Rodvold KA, Gentry CA, Plant GS, Kraus DM, Nickel E, Gross JR. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239-46.
52. 52. Higa GM, Murray WE. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm 1987; 6: 963-6.
53. 53. Kaojarern S, Maoleekoonpairoy S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother 1983; 33: 1406-8.
54. 54. Davis RL, Lehmann D, Stidley CA, Neidhart J. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother 1991; 35: 944-7.
55. 55. Zeitany RG, El Saghir NS, Sathosh-Kumar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34: 702-8.
56. 56. Walpole RE, Myers RH. Probability and statistics for engineers and scientists. 4th ed. New York: Macmillan Publishing Company, 1989: 361.